- Description
- Additional
Description
Details
Description:Rabbit anti-human Twik-related potassium channel 1 protein (TREK-1) polyclonal antibody
Purification: Protein G affinity purified
Product Type:Primary antibody
Target Protein:TREK-1
Immunogen:A synthetic peptide (SASRERPGYTA) derived from the amino acid residue 4-14 of human TREK-1, conjugated with KLH for immunization
Specificity:This antibody reacts with the 47kDa TREK-1 in Jurkat cell extract.
Species Reacitvity:Human and other species with consensus TREK-1 peptide (SASRERPGYTA)
Source:Rabbit
Formulation:Lyophilized in pH 7.4, 0.01M PBS
Reconstitution:Double distilled water is recommended to adjust the final concentration to 1.00mg/mL.
Storage:Store at -20oC
Research Area:Life science research, stem cell factor signalling, cancer research
Background:
TWIK-related potassium channel 1(TREK-1), also known as K2P2.1, is a two pore domain gated potassium channel that is involved with pain reception. TREK-1 is highly expressed in small sensory neurons and is extensively colocalized with TRPV1. TREK-1 is sensitive to noxious stimuli including extracellular pH, temperature, mechanical force, osmotic pressure and other stimuli. TREK-1 is one of the targets for pain mediator and anaesthesia drug.
Application:
ELISA: The antibody (1:500,000 diluted) can detect the TREK-1 peptide coated on ELISA plate at 100ng/well.
Western blot: Dilute approx. 1:3,000 for using in Western blot to detect the 47kDa TREK-1 in Jurkat cell extract.
Fig.1 Western blot analysis of Jurkat cell extract using rabbit anti-trek1.
References:
If research is published using this product, please inform Anogen in order to cite the reference on this datasheet. Anogen will provide one unit of product in the same category as gratitude.
Additional
Additional Information
| Product Specificity | pAb Rabbit anti-Human TREK-1 (K2p2.1) |
|---|---|
| Application | EIA, WB |
| Size | 0.1 mg |
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
一种是奥曲肽微球商品名“善龙”一种是兰瑞肽微球商品名“索马杜林”
两种药物都是纯进口产品因工艺特殊国际上至今都没有仿制品出现
国外已经有了二代长效生长抑素类似物是凝胶预充剂型的长效兰瑞肽
其工艺比微球制剂更先进了一步患者可做到像胰岛素一样进行自我注射
注射周期也比现有的28天注射间隔更长能达到56天或天的注射周期
研发的纳米微球可用于增强比浊，酶联免疫等，粒径均一程度可用于标准品，如果您有降低免疫比浊试剂盒成本的需要，可登陆我们的网站www.nercb.cas.cn查询，也可拨打010-82544957详询。
至于安全性，这是一款被国家食品药品监督管理局（CFDA）批准的有证产品，而CFDA批准三类医疗器械都是十分严格严谨的，所以产品本身安全性肯定没问题啦，不过使用的安全性也跟医生注射技术有关。
我理解就是一个是包裹，一个是镶嵌
